Stay updated on CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Sign up to get notified when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.

Latest updates to the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page
- Check2 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4, reflecting a minor update to the page system. No study content or results were changed.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page now displays Revision: v3.6.3, replacing the previous v3.6.2. This reflects a new version of the page metadata rather than a substantive change to the information shown.SummaryDifference0.0%

- Check31 days agoChange DetectedPage metadata was updated from Revision v3.6.0 to v3.6.2, indicating a minor patch release of the page system. This update does not introduce changes to the study text or data.SummaryDifference0.0%

- Check45 days agoChange DetectedRecruitment status on the study page now shows 'No longer looking for participants', signaling that enrollment is closed. The page also adds new help/navigation items ('How to Read a Study Record', 'Common Questions', 'How to Join a Study'), updates the Intervention/Treatment heading formatting, and includes a revision note 'Revision: v3.6.0'.SummaryDifference0.2%

- Check52 days agoChange DetectedRevision label updated from v3.5.4 to v3.5.5, indicating a new site revision. No specific content changes are indicated by the provided changes.SummaryDifference0.0%

- Check74 days agoChange DetectedThe page's revision label updated from v3.5.3 to v3.5.4, indicating a new release of the site's backend or content management. This change does not alter trial information shown to users.SummaryDifference0.0%

Stay in the know with updates to CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CB-839 Combo vs. Cabozantinib in Metastatic RCC Clinical Trial page.